RGRobert Phillip Gallegos

Robert Phillip Gallegos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert Phillip Gallegos has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Giant Syphilitic Aortic Aneurysm

    by Taufiek Konrad Rajab, Robert P. Gallegos

    Images in Clinical Medicine from The New England Journal of Medicine — Giant Syphilitic Aortic Aneurysm


  • Transmural Atrial Fibrosis after Epicardial and Endocardial Argon-Powered CryoMaze Ablation

    by Robert P. Gallegos, Andrew L. Rivard, Taufiek K. Rajab, B. Chir, Jan D. Schmitto, Matthew T. Lahti, Nicole Kirchhof, Richard W. Bianco

    The CryoMaze procedure is usually limited to endocardial ablation under cardio-pulmonary bypass. Epicardial ablation is considered inferior as endocardial islets of atrial tissue could theoretically remain viable, protected from cryoinjury by epicardial fat and endocardial circulating warm blood. Novel argon-powered cryoprobes with lower ablation temperatures have recently become available. It is unclear if these instruments can reliably induce transmural atrial fibrosis by epicardial cryoablation on the beating heart. Ten sheep were divided into two equal groups. CryoMaze ablations were applied using an argon-powered cryoprobe with an ablation temperature of -185°C. In the control group, standardized ablations (n = 50) were applied endocardially under cardiopulmonary bypass. In the experimental group, corresponding ablations (n = 50) were applied epicardially on the beating heart. Postoperatively the animals were monitored for 30 days. At necropsy, the lesions were explanted and analyzed histologically for evidence of transmural fibrosis. Two animals in the control group and one animal in the experimental group died prematurely. Autopsy of the remaining animals showed that all lesions (n = 70) had retained their structural integrity. In the control group, histology demonstrated transmural fibrosis in 94% (28/30) of the endocardially applied lesions. In the experimental group, histology demonstrated transmural fibrosis in 95% (38/40) of the epicardially applied lesions. Statistical analysis revealed no significant difference between the two groups (p = 0.96). Argon-powered epicardial cryoablation on the beating heart is as efficient in inducing transmural fibrosis as the traditional technique of endocardial ablation under cardio-pulmonary bypass.


  • Open Access

    Post-partum coronary artery dissection

    by Taufiek Konrad Rajab, Zain Khalpey, Robert Phillip Gallegos

    A healthy 32-year-old female presented with NSTEMI 2 weeks following an uneventful pregnancy and caesarian section. Emergent cardiac catheterization demonstrate


  • Cardiac Hemangioma Presenting with Angina Pectoris

    by Taufiek K. Rajab, Zain Khalpey, Lawrence H. Cohn, Robert P. Gallegos

    A 60-year-old female presented with a two-year history of exertional chest pain and progressive dyspnea. Resection of a cardiac hemangioma arising from the area of the bifurcation of the left anterior descending and circumflex coronary arteries resulted in complete resolution of her symptoms. The symptoms were likely caused by coronary steal.

  • Open Access

    Recurrent post-partum coronary artery dissection

    by Taufiek K Rajab, Zain Khalpey, Bernhard Kraemer, Frederic S Resnic, Robert P Gallegos

    Coronary artery dissection is a rare but well-described cause for myocardial infarction during the post-partum period. Dissection of multiple coronary arteries is even less frequent. Here we present a case of recurrent post-partum coronary artery dissections. This unusual presentation poses unique problems for management. A 35 year-old female, gravida 3 para 2, presented with myocardial infarction 9 weeks and 3 days post-partum. Cardiac catheterization demonstrated left anterior descending (LAD) dissection but an otherwise normal coronary anatomy. The lesion was treated with four everolimus eluting stents. Initially the patient made an unremarkable recovery until ventricular fibrillation arrest occurred on the following day. Unsynchronized cardioversion restored a normal sinus rhythm and repeat catheterization revealed new right coronary artery (RCA) dissection. A wire was passed distally, but it was unclear whether this was through the true or false lumen and no stents could be placed. However, improvement of distal RCA perfusion was noted on angiogram. Despite failure of interventional therapy the patient was therefore treated conservatively. Early operation after myocardial infarction has a significantly elevated risk of mortality and the initial dissection had occurred within 24 hours. This strategy proved successful as follow-up transthoracic echocardiography after four months demonstrated a preserved left ventricular ejection fraction of 55-60% without regional wall motion abnormalities. The patient remained asymptomatic from a cardiac point of view.


  • Animal Models for Cardiac Research

    by Richard W. Bianco, Robert P. Gallegos, Andrew L. Rivard, Jessica Voight, Agustin P. Dalmasso


    • 1 May 2007
      • Vol. 16  (3) , 314-23

    Development of a sheep model of atrial fibrillation for preclinical prosthetic valve testing.

    by Andrew L Rivard, Phillip T Suwan, Keyoumars Imaninaini, Robert P Gallegos, Richard Bianco

    Currently, prosthetic heart valve testing is performed on animal models with no underlying cardiovascular pathologies. Unfortunately, unforeseen adverse events may occur when heart valves tested in animals in normal sinus rhythm are implanted in patients suffering from arrhythmias. For example, the Medtronic Parallel valve functioned well in pre-clinical testing, but a high rate of thromboembolic complications appeared when the valve was placed in patients with atrial fibrillation (AF). Given the increasing number of patients afflicted with AF, an animal model of the disorder is needed to more accurately predict a valve's function in the clinical setting. Among methods available for inducing AF, electrophysiological pacing is the most practiced, but the challenges associated with pacing have led to the development of alternative methods of inducing AF These methods include gene transfer and a pharmacologic approach with acetylcholine and catecholamines. Finally, although stem cells have been widely investigated in terms of their therapeutic benefits, the use of their well-reported pro-arrhythmic behavior shows great promise for the development of an AF model in sheep. Such a model would have the potential for detecting adverse outcomes with mechanical heart valves before implantation in the clinical setting.


    • 1 November 2006
      • Vol. 15  (6) , 791-9

    In-vivo experience with the Triflo trileaflet mechanical heart valve.

    by Robert P Gallegos, Andrew L Rivard, Phillip T Suwan, Sylvester Black, Stefan Bertog, Ulrich Steinseifer, Anibal Armien, Matthew Lahti, Richard Bianco

    The in-vivo performance of the Triflo trileaflet mechanical valve was evaluated in an ovine model. The aim of long-term follow up was to gather site-specific performance data demonstrating device safety, as required for regulatory approval of this new valve design, prior to its use in clinical trials. The Triflo trileaflet valve was implanted in 26 sheep using 29-mm mitral (n=8; animal body weight 63.3 +/- 10.3 kg, age 112.0 +/- 30.7 weeks) or 21-mm aortic mechanical valves (n=19; body weight 73.0 +/- 4.36 kg, age 112.6 +/- 23.6 weeks) using standard techniques. Animals were allocated to 150- or 365-day survival cohorts. The 150-day cohort was further subdivided into mitral valve (n=6) and aortic valve (n=11) implants. The 365-day cohort was organized into aortic (n=7) and mitral (n=2) implants. Angiography, echocardiography, and pathology were performed to assess valve performance. Angiographically monitored pressure measurements for the trileaflet mitral valve at 150 and 365 days were within established ranges in terms of mean aortic pressure, systolic and diastolic aortic pressure, and left ventricular end-diastolic pressure. In animals receiving a mitral valve the transvalvular gradient was 3.5 +/- 0.71 mmHg at 365 days, and 0.2 +/- 0.4 mmHg at 150 days. The Triflo mitral valve had only mild (physiologic) regurgitation. Cardiac output was within normal limits in animals receiving the Triflo valve in the aortic position. Laboratory values reflected no ongoing infection or destruction of blood cells as a result of device implantation. No significant abnormality was noted at necropsy in any animal, except for evidence of thromboembolic events in the kidneys (4-20%). Pathological evaluation was reflected by mild to moderate fibrous tissue formation at the inflow orifice (n=15), and minimal growth was observed in the outflow tract of one valve. This was consistent with that seen in sheep implanted with a standard St. Jude Medical bileaflet valve. The study results showed the Triflo valve to perform to safety levels comparable with those of the standard St. Jude Medical bileaflet design, when implanted in the aortic and mitral positions. Additional analysis of historic control data suggested that the trileaflet valve design may offer a reduction in outflow tract obstruction by allowing for a greater effective orifice area index when compared to an equal-sized-orifice bileaflet valve. Notably, the Triflo valve was associated with a statistically significant reduction in myocardial hypertrophy, further reducing the potential for patient-prosthesis mismatch. Overall, the Triflo valve appeared to more closely emulate the hemodynamic properties of the native tissue valve than the traditional bileaflet design. Hence, the trileaflet design may offer the function of a tissue valve while retaining the durability of the mechanical valve.


  • Selection of prosthetic heart valves

    by Robert P. Gallegos

    Cardiovascular surgery for the repair or replacement of diseased heart valves has continually improved since its introduction in the early 1960s. Despite advances in prosthetic heart valve design, to date there is no valve that is comparable to the native human valve with respect to durability, risk of thrombosis, and overall hemodynamic function. Although bioprosthetic devices are similar to the native valve with respect to thrombogenicity, durability is a significant concern, particularly in younger patients. Approximately 45% of implanted bioprosthetic valves fail at 10 years. In contrast, mechanical prostheses have a significantly lower incidence of structural failure, with an implantation life of greater than 20 years, and are thus more often used for patients under the age of 65. Unfortunately, significant hemodynamic and thrombotic issues have yet to be resolved with the latest generation of mechanical valves. Thus, careful analysis of patient factors and valve-related complications must be considered when treatment of heart valve disease is offered to the patient. The purpose of this review is to discuss the current recommendations for surgical intervention for heart valve disease.